Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' reply

Aliment Pharmacol Ther. 2018 Nov;48(9):1029-1030. doi: 10.1111/apt.14974.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Crohn Disease*
  • Humans
  • Inflammatory Bowel Diseases*
  • Infliximab

Substances

  • Antibodies, Monoclonal
  • Infliximab